EPHA2 and cancer: Proteolytic cleavage of EphA2 by membrane type 1 matrix metalloproteinase (MT1-MMP) on the surface of cancer cells converts EphA2 from a ligand-bound to a ligand-unbound form in many cancer types (14–18).